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INTRODUCTION 
Platelet transfusion is an effective therapy to control bleeding in thrombocytopenic patients. Unfortunately, blood 
platelet units are generally stored in blood banks for 3-5 days; thereafter they are discarded
1, 2
. For preserving platelets 
for a long period, a number of attempts have been taken to develop substitutes for platelets, as possible alternatives to 
currently available platelet concentrates. A number of studies have shown that platelet preparations with impaired 
metabolic or functional integrity still retain a certain degree of hemostatic property
3-8
.  Infusible platelet membrane 
(IPM) prepared from fresh or outdated human platelets have been developed as an alternative to standard platelet 
concentrates, with the additional advantage of long shelf life and increased pathogen safety and have confirmed useful 
in shortening bleeding time in rabbits with experimentally induced thrombocytopenia
9-13
. The preliminary clinical study 
of lyophilized platelet material in patients with secondary thrombocytopenia showed no toxicity or thromboembolic 
sequelae
14
. Evaluation of the thrombogenicity of IPM, using the method of Wessler et al.
15
, indicated that IPM is not 
thrombogenic
10
. In normal human volunteers, infusions of IPM were well tolerated and had no effect on biochemical or 
coagulation parameters and no evidence of immunogenicity was reported
16
. On the other hand, the earliest trials with 
IPM preparations were not successful in vivo and produced considerable distress in experimental animals
17,18
. This line 
of research was postponed for nearly three decades until experiments in thrombocytopenic rabbits provided preclinical 
evidence of the preparations haemostatic efficacy without significant morbidity
9
.  
The crucial step in the quality control insurance of different pharmaceutical products requires absence of fever-inducing 
contaminants (pyrogens), especially in drugs intended for the parenteral application. Given the seriousness of this issue, 
rabbit pyrogen test has been taken into consideration of European Pharmacopoeia as indicated general chapter on 
Pyrogens; 2.6.8.  Since 1942, the rabbit pyrogen test (RPT) has been established as a golden standard for testing 
various pyrogens (Gram-negative endotoxins, non-endotoxin pyrogens, fungal pyrogens). Optionally, the Limulus-
Amebocyte-Lysate test (LAL) is used as a highly specific test for detection of Gram-negative bacteria endotoxin, but it 
fails to detect non-endotoxin pyrogens and therefore can not be used solely, instead of RPT. The principle of proposed 
tests is measurement of proinflammatory cytokines such as tumor necrosis factor (TNF), interlukin ( IL-1, IL-6) 
released from human blood cells in response to the presence of exogenous pyrogens
19
. Bacterial products and toxins 
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exemplify exogenous mediators. Endogenous mediators are classified based on source or origin as plasma derived and 
cell or tissue derived. 
In this paper we want to show that our lyophilized IPM which is prepared from fresh and outdated human platelets is 
safe and has no adverse effects of pyrogenicity or fever induction due to bacterial contamination, proinflamatory 
cytokines and membrane fragments of leukocytes and platelets, at the various injection doses during rabbit pyrogen test 
study.   
MATERIALS AND METHODS 
Preparation of IPM   
IPM is prepared from 58 fresh and outdated platelet units of Tehran Blood Transfusion Center. The units were pooled 
and centrifuged for 15 min at 1000 RPM in order to remove contaminating red and white cells. The supernatant was 
centrifuged for 30 min at 2500 RPM to remove plasma. The precipitate was suspended in 150 ml of physiological 
saline solution (0.9 g%). For lysis and disruption of platelets, freeze-thaw procedure was repeated three times at -50°C 
and room temperature for 24 and 3 hours, respectively. The solution was then washed twice with physiological saline 
solution to remove intracellular components by centrifugation (30 min at 2500 RPM). The precipitate was then 
suspended again in a 94 ml of the same solution. 
Pasteurization  
The IPM suspension with 0.4 M sodium caprylate concentration was prepared and heated at 60°C for 20 hours to 
inactivate possible viral or bacterial contaminants and was then formulated with sucrose 1 M and human serum 
albumin 0.1%
12
. 
Lyophilization   
After filling and capping, the vials were lyophilized by Freeze-Dryer (Usifroid Model SMH 150) in an aseptic 
condition for three days. 
Sterility Test 
The test for sterility was carried out under aseptic conditions according to the EU Pharmacopoeia monograph (general 
chapter on sterility 2.6.1).   
Particle size assay 
We used a particle-sizing instrument (Malvern Zetasizer Nano ZS, UK) to measure the angular distribution of light 
scattered from a sample illuminated by a laser. The corresponding size distribution was calculated by using the 
software supplied with the instrument.    
Rabbit pyrogen test 
Healthy, adult rabbits of either sex, weighing not less than 1.5 kg were purchased from Tehran Institute Pasteur and the 
test for pyrogens was performed according to the EU Pharmacopoeia monograph (Ph. Eur. general chapter on 
Pyrogens; 2.6.8). The lyophilized IPM was reconstituted with a pyrogen-free distilled water and was injected slowly 
into the marginal vein of the ear of each rabbit over a period not exceeding 4 minutes. The temperature degrees of the 
animals were recorded, beginning before injection and continuing for 3 hours after injection of the IPM being 
examined.  The initial and maximum temperatures for each rabbit were determined before and after the injection of 
IPM respectively by pyrogen testing instrument (PD 85 instrument, Ellab, Copenhagen, Denmark). The amount of the 
samples to be injected on five groups (three rabbits each) were1.0, 2.0, 4.0, 6.0 and 9.0 mg per kg of body weight. The 
volume of the injection was less than 10 ml per kg of body weight. 
RESULTS 
In our previous investigations the effectiveness of IPM was demonstrated by the reduction in the bleeding time in 
thrombocytopenic rabbits
11
 with its dose-dependent response property
13
. In this study we investigated that our IPM 
product pyrogen levels in sterile are within established limits according to sterility and pyrogenecity requirements of 
the European Pharmacopoeia for injectable drug products.  
The results of rabbit pyrogen test of infusible platelet membrane are summarized in Table I.  
The principal of the test 
The test consists of measuring the rise in body temperature inducing in rabbits by the intravenous injection of a sterile 
solution of the IPM being examined. 
Determination of the initial and maximum temperatures 
The initial temperature of each rabbit is the mean of two temperature readings recorded for that rabbit at an interval of 
30 minutes in the 40 minutes immediately preceding the injection of the material being examined. The maximum 
temperature of each rabbit is the highest temperature recorded for that rabbit in the 3 hours after injection. The 
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difference between the initial temperature and the maximum temperature of each rabbit is taken to be its response and 
the sum of differences of each group were calculated (Table I).  
 
Table I: Results of rabbit pyrogen test of infusible platelet membrane (IPM) 
Number of 
rabbits* 
(C°) 
Dose of IPM injection 
(mg/kg) 
Summed 
response
**
 
(C°) 
Material passes if 
summed response 
does not exceed
*
 (C°) 
Pass/Fail status  
3 1.0 0.1 1.15 Pass 
3 2.0 0.2 1.15 Pass 
3 4.0 0.5 1.15 Pass 
3 6.0 0.7 1.15 Pass 
3 9.0 1.0 1.15 Pass 
*  Test for pyrogens was performed according to the EU Pharmacopoeia monograph (Ph. Eur. general chapter on Pyrogens (2.6.8). 
** The sum of difference between the mean initial temperature (before injection) and the maximum temperature (after injection) of 
each rabbit                       
 
Interpretation of results 
The test was performed on a group of three rabbits. The summed response of each group does not exceed 1.15° C and 
therefore all various doses of IPM were passed according to the EU Pharmacopoeia limits. Statistical analysis showed 
that there is a strong correlation between the amount of administrated dosage and summed response temperature of 
each group (r =0.996).  
Characteristics of IPM   
The lyophilized IPM was prepared in an aseptic condition with acceptable solubility test during reconstitution and 
mean particle size of 380 nm (Table II). The sterility test was passed and confirmed our efficient pasteurization 
procedure as a pathogen inactivation method (Table II). Haemostatic effect of IPM has previously been demonstrated 
by Nasiri et al. in animal studies
11,13
. The maximum decrease in the percentage of bleeding time was observed at 2 h 
after and this haemostatic effect was no longer detectable after 24 h of IPM administrations. 
Table II: Characteristics of lyophilized infusible platelet membrane (IPM) 
Total protein (g/dL) 0.2 
Solubility test (min) Less than 10 min 
Mean particle size (nm) 380 
pH 7.1 
Sterility test Pass 
In vivo haemostatic effect (bleeding time) Shortening of the bleeding time in thrombocytopenic 
rabbits was observed after 2 hours of IPM infusion 
Rabbit Pyrogen test Pass 
 
DISCUSSION 
Parenteral preparations have to be pyrogen-free because administration of pyrogens may induce fever, shock or even 
death. The severity of the adverse reactions depends on the concentration and biological activity of the respective 
pyrogen. There is a broad spectrum of pyrogens which are classified into endotoxin and non-endotoxin pyrogens. 
Endotoxins, representing the lipopolysaccharides (LPS) of the cell wall of Gram-negative bacteria, are the best 
characterised and the most potent pyrogens. The structural identity of most non-endotoxin pyrogens has not yet been 
clarified. Examples of pyrogens from Gram-positive bacteria are the lipoteichoic acids and peptidoglycans which are 
constituents of the bacterial cell wall
20
.  
Currently, there are two tests described in the European Pharmacopoeia which are related to pyrogen testing of 
parenteral medicinal products: the rabbit pyrogen test (RPT) which is considered to detect most of the pyrogens, i.e. 
endotoxins and non-endotoxin pyrogens, and the bacterial endotoxin test, i.e. Limulus polyphemus amoebocyte Lysate- 
test (LAL-test) which is used to detect or quantify endotoxins of Gram-negative bacteria.  
Lyophilized IPM may have both endotoxins and non-endotoxin pyrogens due to the presence of higher bacterial 
contamination of platelet concentrates in comparison with the other blood components and proinflamatory cytokines 
such as tumor necrosis factor (TNF), interlukin ( IL-1, IL-6) that may be accumulated during storage of platelet 
concentrates and also microparticles or membrane fragments of residual leukocytes and platelets. In addition, numerous 
laboratory studies have shown that a wide variety of biologic response modifiers, including cytokines, chemokines, 
complement fragments, histamine, and lipids, accumulate in platelet products during storage
21
. 
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Febrile non-hemolytic transfusion reactions (FNHTRs) are common in recipients of platelet concentrates. These can 
raise a fever by 1 °C or more within the first 4 h of transfusion and normalization of the temperature within 48 h, if 
transfusion of a bacterially contaminated blood product can be excluded and if no signs of hemolysis are found. 
Blumberg et al. studied a platelet-derived substance, soluble CD40 ligand (sCD40L, CD154), in supernatants of platelet 
concentrates as possible cause of FNHTRs
22
. These authors indicate that platelet-associated CD40L and sCD40L 
induce prostaglandin E2 synthesis (inducing fever) and synthesis of pro-inflammatory cytokines in a variety of cells in 
the recipient, including endothelial cells and fibroblasts
23,24
. 
Our experiment showed that IPM is safe, tolerable and it does not induce fever in rabbits even at high doses of IPM 
such as 9.0 mg/kg in comparison with the standard-dose
10
 of 2.0 mg/kg because, higher doses of disintegrated platelets 
had undesirable side effects in the experimental dogs
18
. 
CONCLUSION 
In this study, it may be concluded that IPM as a platelet substitute can demonstrate safety with the acceptable 
tolerability without pyrogenecity. In spite of challenges in demonstrating its efficacy, the investigations should continue 
on different aspects of the novel IPM product to provide maximal clinical benefits with minimal risk of 
complications
8,25,26
. On the other hand, recent concerns of various complications have been raised about transfusion 
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The advantages of IPM over conventional platelet concentrates include: 
• improved shelf life, ease of storage and use 
• reduced endotoxin and non-endotoxin pyrogens 
• reduced viral and bacterial load due to an applied pasteurization method 
• possible fever reduction induced by post-transfusion reactions due to removal of contaminating red cells, white cells, 
intracellular and extracellular proinflamatory mediators and other biologic response modifiers during freeze-thawing 
and washing steps.   
It should be considered that platelet substitutes which aim to be alternatives to the current platelet products should 
demonstrate a clear benefit-to-risk ratio before they are considered for clinical trials. However, further animal studies 
are required to more fully define the safety or efficacy of IPM as a platelet substitute. Although much remains to be 
investigated, anyway, it should be considered that the success of these efforts will affect patient care in transfusion 
medicine. 
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